Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer starts when the cells in the cervix begin to grow abnormally. These changes in the cells often take years to ...

which had previously won accelerated approval in 2021 for the treatment of patients with recurrent or metastatic cervical cancer. Tivdak, which Pfizer acquired through its acquisition of Seagen in ...

While cervical cancer screening is a routine part of health care for Canadians, many fall through the cracks. Robby Mukonjero, a 63-year-old who moved to Canada from Kenya in 2023, had never been ...